glenn noronha  clearside biomedical inc  zoominfocom glenn noronha clearside biomedical inc profile  biography  bloomberg feedback glenn noronha exec vpresearch  development clearside biomedical inc career history exec vpresearch  development clearside biomedical inc present vpresearch  development sucampo pharmaceuticals inc  chief scientific officer jw theriac inc  global headproject alcon laboratories inc  various positions targegen inc  various positions medtronic minimed former show more website wwwclearsidebiocom corporate information address  old alpharetta road suite  alpharetta ga  united states phone  fax  web url wwwclearsidebiocom from the web personal information education loyola university maryland phd memberships other memberships association for research in vision  ophthalmology arvo member university of california at irvine fellow sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data  facebook facebook   ？ facebook ？？：？，。english us한국어français francebahasa indonesiapolskiespañolportuguês brasildeutschitalianomessengerfacebook liteinstagramcookie facebook   clearside biomedical inc announces promotion of glenn noronha phd to chief scientific officer and jennifer m kissner phd to vice president clinical development nasdaqclsd english français register sign in clearside biomedical inc announces promotion of glenn noronha phd to chief scientific officer and jennifer m kissner phd to vice president clinical development august    et  source clearside biomedical inc alpharetta ga aug   globe newswire  clearside biomedical inc nasdaqclsd a latestage clinical biopharmaceutical company developing firstinclass drug therapies to treat blinding diseases of the eye today announced that glenn noronha phd has been promoted to chief scientific officer and jennifer m kissner phd has been promoted to vice president clinical development both drs noronha and kissner will assume their roles immediately and will report to daniel h white ceo and president of clearside biomedical dr noronha has served as executive vice president of research and development for clearside since august  leading the scientific affairs and clinical development of the company’s portfolio dr noronha has  years of experience in clinical and nonclinical research and development and product development with  of the years being in ophthalmology research and clinical development at alcon sucampo and targegen in dr noronha’s role as chief scientific officer he will continue to be responsible for the strategic development of clearside’s scientific innovation and the global vision for clearside’s product development to treat sightthreatening diseases he will also lead strategy and design for all programs in addition to being responsible for regulatory affairs and quality assurance efforts in order to meet clearside’s goal of becoming a fully integrated ophthalmic pharmaceutical company dr kissner joined clearside in august  as senior director development and has led clearside’s drug development programs for macular edema associated with noninfectious uveitis currently in phase  and wet agerelated macular degeneration amd which is currently in preclinical development with an investigational new drug ind submission to the us food and drug administration expected in the second half of  dr kissner has  years of clinical development experience for entities addressing sightthreatening diseases in positions at ophthalmology companies such as alcon and acucela in dr kissner’s new role she will be responsible for leading the company’s clinical development strategy and team efforts by overseeing all aspects of the design implementation execution and management of clinical trial programs “jennifer and glenn represent a group of gifted researchers at clearside who share a mission to treat patients suffering from sightthreatening diseases” said white “they have the level of experience and accomplishment that clearside seeks to lead our scientific efforts to complete the development of valuable medicines like zuprata™ using suprachoroidal drug delivery” about clearside biomedical inc clearside biomedical inc headquartered in alpharetta ga is a publiclytraded latestage clinical biopharmaceutical company developing innovative firstinclass drug therapies to treat blinding diseases of the eye using clearside’s proprietary suprachoroidal space scs™ microinjector to reach diseased tissue through the suprachoroidal space clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye clearside has a portfolio of clinical and preclinical programs using drug administration through the suprachoroidal space to provide a route of access to treat diseases of the backoftheeye like retinal vein occlusion rvo uveitis wet amd and diabetic macular edema dme clearside is currently enrolling patients in a phase  clinical trial peachtree for the treatment of patients with macular edema associated with noninfectious uveitis and has initiated indenabling studies for the treatment of wet amd visit wwwclearsidebiocom for more information  contacts company charles deignan chief financial officer  charliedeignanclearsidebiocom investors matthew beck the trout group  mbecktroutgroupcom related articles other press releases by clearside biomedical inc clearside biomedical announces first patient randomized in phase  clinical trial of clsta used together with eylea in patients with diabetic macular edema july    clearside biomedical inc to participate in  jmp securities life sciences conference june    clearside biomedical’s tanzanite extension study in patients with macular edema associated with retinal vein occlusion presented at the th annual macula society meeting june    clearside biomedical inc announces first quarter  financial results and provides corporate update may    clearside biomedical inc to report first quarter  financial results on may   – conference call to follow may     other news releases in directors and officers in the last  days profile clearside biomedical inc   subscribe via rss  subscribe via atom  javascript alpharetta georgia united states   httpwwwclearsidebiocom contact data contacts company charles deignan chief financial officer  charliedeignanclearsidebiocom investors matthew beck the trout group  mbecktroutgroupcom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files clearside biomedical inc logo logo url  copy the link below formats available original medium small tags clearside bio promotions zuprata suprachoroidal drug delivery sight threatening diseases uveitis amd newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved glenn noronha  seattle wa  intelius sign in we found glenn noronha in seattle wa glenn noronha intelius found that glenn noronha is a male between  and  years old from seattle wa we have connected them to  addresses  phones and  relatives or associates get report now age glenn noronha is in his s glenn has lived in seattle wa westwood ca irvine ca glenns relatives khanhlinh nguyen maulik singh mollie singh glenn noronha zodiac signaries gendermale professional status chief sales officer at theriac pharmaceuticals get report now want to know more about glenn get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about glenn or use our people search engine to find others get background check on glenn noronha get a criminal check on glenn noronha get a public record report on glenn noronha get a people search report on glenn noronha glenn noronhas contact information known cities lived in find out where glenn noronha has lived as well as glenn noronhas phone numbers and email addresses glenn noronha has lived in  states washington address for glenn noronha   a n seattle wa has lived in seattle wa westwood ca get full address report phone numbers associated with glenn noronha    atlanta ga    seattle wa    fort worth tx get full phone report email addresses associated with glenn noronha gacom ganet gacom get email report glenn noronhas professional information information regarding glenn noronhas professional history find out previous places glenn noronha has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act glenn noronha has worked at  place company theriac pharmaceuticals title chief sales officer glenn noronhas experience title chief sales officer company theriac pharmaceuticals job details additional professional information on glenn noronha see glenn noronhas linkedin profile glenn noronhas social network and potential email matches find out potential social network profiles and potential email usernamed for glenn noronha glenn noronhas known social networks and potential email matches find all of glenn noronhas social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches glenn noronha username matches glennnoronha noronhaglenn glennnoronha noronhaglenn glennnoronha noronhaglenn glennnoronha noronhaglenn gnoronha popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches g noronha intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here sucampo pharmaceuticals appoints glenn noronha phd as vice president research and development  business wire sucampo pharmaceuticals appoints glenn noronha phd as vice president research and development download full size small preview thumbnail glenn noronha phd vice president of research and development sucampo pharma americas llc photo sucampo pharmaceuticals inc paginationprevious paginationnext glenn noronha phd vice president of research and development sucampo pharma americas llc photo sucampo pharmaceuticals inc full size small preview thumbnail full size small preview thumbnail september    pm eastern daylight time bethesda mdbusiness wiresucampo pharmaceuticals inc nasdaq scmp today announced that glenn noronha phd has joined sucampo pharma americas llc spa as vice president of research and development reporting to ryuji ueno md phd phd chairman chief scientific officer and chief executive officer he will assist with strengthening and leading sucampo’s us rd functions dr noronha is responsible for the development of the overall product portfolio from research through approval dr noronha also was named to sucampos global rd leadership team which is headed by dr ueno and includes taryn joswick vice president clinical development of spa birgit roerig phd vice president pharmacology and toxicology at spa peter lichtlen md phd senior medical officer and vice president european operations of sucampo ag sag takashi sekida phd vice president research planning  business development at sucampo pharma ltd spl and gayle dolecek pd mph executive advisor rd affairs spa spa sag and spl are whollyowned subsidiaries of spi dr ueno said “we welcome dr noronha to sucampo and look forward to his contributions in strengthening our expertise particularly in ophthalmology as we prepare for the launch of rescula his extensive drug development experiences from preclinical to clinical and knowledge of ophthalmology oncology and immune and inflammatory mediated diseases will add great value to our rd pipeline for new indications of our prostonebased products amitiza® and rescula® as well as to other compounds based on our proprietary prostone technology additionally sucampo will benefit from his experience of taking research findings into the clinic” dr noronha joins sucampo from jw theriac inc a pharmaceutical company focused on new drug research and development which he joined in july  as chief scientific officer responsible for translational efforts in the oncology therapeutic area at jw theriac he successfully identified and proposed opportunities for research and innovation along with the assessment of risks and technical hurdles prior to jw theriac dr noronha had leadership roles in retina development at alcon laboratories inc now part of novartis from november  to july  with global responsibilities for planning and executing all stages of retina development including working with clinical regulatory scientific nonclinical and technical colleagues for both small molecules and biologics previously from june  to july  dr noronha worked at targegen inc now acquired by sanofiaventis and held several positions of increasing responsibility among them senior scientist group leader and director at targegen he delivered three of the five small molecule candidates into development that were entered into clinical trials one small molecule candidate resulted in successful phase  results dr noronha earned his phd in organometallic chemistry from loyola university chicago and conducted postdoctoral research at the university of california irvine in protein structural and bioorganic chemistry dr noronha is a member of the association for research in vision and ophthalmology arvo and is named on  composition of matter and use patents for drugs in ophthalmology oncology immune and inflammatory diseases and in continuous glucose sensing he is the author of more than  peerreviewed articles and more than  scientific presentations at national and international forums about sucampo pharmaceuticals inc sucampo pharmaceuticals inc is a global pharmaceutical company focused on innovative research discovery development and commercialization of proprietary drugs based on prostones the therapeutic potential of prostones which occur naturally in the human body as a result of enzymatic catalysis by pgdh of eicosanoids and docosanoids was first identified by ryuji ueno md phd phd sucampo’s chairman and ceo dr ueno founded sucampo pharmaceuticals in  with sachiko kuno phd founding ceo and currently executive advisor international business development and a member of the board of directors for more information please visit wwwsucampocom amitiza® is a registered trademark of sucampo ag rescula® is a registered trademark of rtech ueno ltd and has been licensed to sucampo sucampo forwardlooking statement this press release contains forwardlooking statements as that term is defined in the private securities litigation reform act of  these statements are based on managements current expectations and involve risks and uncertainties which may cause results to differ materially from those set forth in the statements the forwardlooking statements may include statements regarding product development product potential future financial and operating results and other statements that are not historical facts the following factors among others could cause actual results to differ from those set forth in the forwardlooking statements the impact of pharmaceutical industry regulation and health care legislation sucampos ability to accurately predict future market conditions dependence on the effectiveness of sucampos patents and other protections for innovative products the risk of new and changing regulation and health policies in the us and internationally and the exposure to litigation andor regulatory actions no forwardlooking statement can be guaranteed and actual results may differ materially from those projected sucampo undertakes no obligation to publicly update any forwardlooking statement whether as a result of new information future events or otherwise forwardlooking statements in this presentation should be evaluated together with the many uncertainties that affect sucampos business particularly those mentioned in the risk factors and cautionary statements in sucampos form k for the year ended dec   which sucampo incorporates by reference photosmultimedia gallery available httpwwwbusinesswirecomcgibinmmgcgieidlangen contacts sucampo pharmaceuticals incsilvia taylor staylorsucampocomorkate de santis kdesantissucampocom release summary sucampo pharmaceuticals appoints glenn noronha phd as vice president research and development contacts sucampo pharmaceuticals incsilvia taylor staylorsucampocomorkate de santis kdesantissucampocom search advanced news search advanced news search log in sign up clearside biomedical inc names glenn noronha phd executive vice president research and development  business wire clearside biomedical inc names glenn noronha phd executive vice president research and development august    am eastern daylight time alpharetta gabusiness wireclearside biomedical inc a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sightthreatening diseases today announced glenn noronha phd has been named to the position of executive vice president research and development noronha has  years of experience in the pharmaceutical industry where he served across clinical and nonclinical research and development product development and other leadership roles he has led multidisciplinary teams in many fields of medicine including ophthalmology oncology and immunological and inflammatory diseases “glenn has had extensive experience in planning and executing all stages of drug development that targets retinal diseases including working with clinical regulatory scientific nonclinical and technical areas for both small molecules and biologics” said daniel white clearside’s president and ceo “he will add profound value to our rd program and to the further development of our portfolio” most recently noronha was vice president research and development at sucampo pharma americas llc prior to sucampo he was chief scientific officer for jw theriac inc a pharmaceutical company focused on new drug research and development in the oncology therapeutic area from  through  as global project head noronha was responsible for execution of strategy in six ophthalmology projects across all stages of development in alcon laboratories’ retina therapeutic area previously noronha held several positions of increasing responsibility at targegen inc and medtronic minimed inc noronha received his phd from loyola university chicago and conducted his postdoctoral research at the university of california irvine he is a member of the association for research in vision and ophthalmology arvo and is named on  pending or issued composition of matter and use patents for drugs in ophthalmology oncology immune and inflammatory diseases and in continuous glucose sensing he is the author of more than  peerreviewed articles and more than  scientific presentations at national and international forums about clearside biomedical inc clearside biomedical inc headquartered in alpharetta ga is a clinicalstage ophthalmic pharmaceutical company that develops and commercializes targeted therapeutics to treat sightthreatening diseases clearside treats the pathological changes to the blood retinal barrier that lead to retinal blindness by delivering therapeutics through the suprachoroidal space to the retina and choroid using a proprietary microinjection dosage form clearside biomedical was founded by an executive team with extensive development and revenue growth expertise this team strives for better delivery and performance of its therapeutic agents to improve the standard of care for patients with retinal and choroidal disease visit wwwclearsidebiomedicalcom for more information contacts clearside biomedical inccharles deignan charliedeignanclearsidebiocom release summary clearside biomedical inc an ophthalmic company that develops targeted therapeutics to treat eye diseases names glenn noronha phd executive vice president research and development contacts clearside biomedical inccharles deignan charliedeignanclearsidebiocom search advanced news search advanced news search log in sign up clearside biomedical inc announces promotion of glenn noronha phd to chief scientific officer and jennifer m kissner phd to vice president clinical development – pm nasdaqclearside biomedical inc announces promotion linkedin cempra appoints john bluth executive type in your search and press enter nasdaq clearside biomedical inc announces promotion of glenn noronha phd to chief scientific officer and jennifer m kissner phd to vice president clinical developmentnasdaqnasdaq infectious diseases market newsclearside biomedical inc announces promotion of glenn noronha phd to chief scientific officer and jennifer m kissner phd to vice president clinical development bynasdaq market newsaugust   facebook twitter linkedin linkedinshares alpharetta ga aug   globe newswire  clearside biomedical inc nasdaqclsd a latestage clinical biopharmaceutical company developing firstinclass drug therapies to treat blinding diseases of the eye today announced that glenn noronha phd has been promoted to chief scientific officer and jennifer m kissner phd has been promoted to vice president clinical development both drs noronha and kissner will assume their roles immediately and will report to daniel h white ceo and president of clearside biomedical dr noronha has served as executive vice president of research and development for clearside since august  leading the scientific affairs and clinical development of the company’s portfolio dr noronha has  years of experience in clinical and nonclinical research and development and product development with  of the years being in ophthalmology research and clinical development at alcon sucampo and targegen in dr noronha’s role as chief scientific officer he will continue to be responsible for the strategic development of clearside’s scientific innovation and the global vision for clearside’s product development to treat sightthreatening diseases he will also lead strategy and design for all programs in addition to being responsible for regulatory affairs and quality assurance efforts in order to meet clearside’s goal of becoming a fully integrated ophthalmic pharmaceutical company dr kissner joined clearside in august  as senior director development and has led clearside’s drug development programs for macular edema associated with noninfectious uveitis currently in phase  and wet agerelated macular degeneration amd which is currently in preclinical development with an investigational new drug ind submission to the us food and drug administration expected in the second half of  dr kissner has  years of clinical development experience for entities addressing sightthreatening diseases in positions at ophthalmology companies such as alcon and acucela in dr kissner’s new role she will be responsible for leading the company’s clinical development strategy and team efforts by overseeing all aspects of the design implementation execution and management of clinical trial programs “jennifer and glenn represent a group of gifted researchers at clearside who share a mission to treat patients suffering from sightthreatening diseases” said white “they have the level of experience and accomplishment that clearside seeks to lead our scientific efforts to complete the development of valuable medicines like zuprata™ using suprachoroidal drug delivery” about clearside biomedical inc clearside biomedical inc headquartered in alpharetta ga is a publiclytraded latestage clinical biopharmaceutical company developing innovative firstinclass drug therapies to treat blinding diseases of the eye using clearside’s proprietary suprachoroidal space scs™ microinjector to reach diseased tissue through the suprachoroidal space clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye clearside has a portfolio of clinical and preclinical programs using drug administration through the suprachoroidal space to provide a route of access to treat diseases of the backoftheeye like retinal vein occlusion rvo uveitis wet amd and diabetic macular edema dme clearside is currently enrolling patients in a phase  clinical trial peachtree for the treatment of patients with macular edema associated with noninfectious uveitis and has initiated indenabling studies for the treatment of wet amd visit wwwclearsidebiocom for more information  contact contacts company charles deignan chief financial officer  charliedeignanclearsidebiocom investors matthew beck the trout group  mbecktroutgroupcom facebook twitter linkedin linkedinshares nasdaq market newsclick here to email authornext storycempra appoints john bluth executive vice president investor relations and corporate communicationsprev storymorphosys ag reports results for the first six months of subscribe to pmfollow usexperts on calljohn weinman phdhealth psychologybud bilanichsuccess coachchris dowdpatient loyaltyjeffrey d erblife sciences medical strategy jessica brueggemanpatientprovider dialoguerick ratliffemrehr connectionsbrenda snowauthentic patient voiceamy groggrare disease  orphan drug commercialization don feilerbrand engagementrichard meyerdtc marketingerik daltonhcp engagement get in touch with pm experts on calladsyou may also likenasdaqnasdaq mental health market newsdoctors administrative solutions acquires conxit technology group forms national health it  management solutions firm das healthtampa fla jan   globe newswire  united by a common business culture nasdaq market newsjanuary  nasdaqnasdaq mental health market newslightlake therapeutics inc announces collaboration with nida and the perelman school of medicine at the university of pennsylvanianew york dec   globe newswire  lightlake therapeutics inc “lightlake” otcqblltp a nasdaq market newsjanuary  nasdaqnasdaq mental health market newscaresource foundation awards  million to ohio nonprofit organizations in dayton ohio dec   globe newswire  the caresource foundation has announced the nasdaq market newsjanuary